Keyphrases
11-dehydrocorticosterone
75%
4E-binding Protein 1
25%
Adverse Metabolic Effects
25%
Atrogin-1
25%
Atrophy
25%
C2C12
25%
Clinical Features
25%
Corticosterone
75%
Cortisol
75%
Cortisone
75%
Cushing's Syndrome
25%
Endogenous Glucocorticoids
25%
Forkhead Box O3a
25%
Glucocorticoid Excess
50%
Growth Factors
25%
Health Burden
25%
Human Myoblasts
25%
Human Myotubes
75%
Hydroxysteroid Dehydrogenase
100%
Insulin-like
25%
Insulin-like Growth factor-1
25%
Intramyocellular
100%
Mammalian Target of Rapamycin (mTOR)
25%
Metabolic Pathway
25%
Metabolic Processes
25%
Molecular Mechanism
25%
MRNA Expression
50%
Muscle Mass
25%
Muscle Protein
25%
Muscle RING Finger 1
25%
Muscle Size
25%
Muscle Wasting
25%
Myoblast Proliferation
50%
Myopathy
25%
Myostatin
25%
Myotubes
100%
Phosphorylation
50%
Proliferative Activity
25%
Protein Degradation
100%
Protein Homeostasis
25%
Protein Metabolism
100%
Protein Reduction
25%
Protein Synthesis
100%
Receptor Modulation
25%
Skeletal muscle
25%
Skeletal muscle Atrophy
25%
Type I Inhibitor
25%
Biochemistry, Genetics and Molecular Biology
Binding Protein
16%
C2C12
16%
Corticosterone
50%
Cortisol
50%
Cortisone
50%
Glucocorticoid
100%
Hydroxysteroid Dehydrogenase
100%
Insulin-Like Growth Factor
16%
Insulin-Like Growth Factor 1
16%
Mechanistic Target of Rapamycin
16%
Messenger RNA
33%
Metabolic Pathway
16%
Myostatin
16%
Protein Biosynthesis
66%
Protein Catabolism
66%
Protein Homeostasis
16%
Protein Metabolism
100%
Skeletal Muscle
33%
Synapsin I
33%
Pharmacology, Toxicology and Pharmaceutical Science
Atrogin 1
16%
Clinical Feature
16%
Corticosterone
50%
Cortisone
50%
Cushing Syndrome
16%
Dehydrocorticosterone
50%
Glucocorticoid
100%
Hydrocortisone
50%
Hydroxysteroid Dehydrogenase
100%
Initiation Factor 4E Binding Protein 1
16%
Insulin-Like Growth Factor 1
16%
Mammalian Target of Rapamycin
16%
Messenger RNA
33%
Muscle Atrophy
33%
Muscle Protein
16%
Myopathy
16%
Myostatin
16%
Receptor
16%
Somatomedin
16%
Synapsin I
16%